Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric Derisomaltose in Children With Iron Deficiency Anemia
NCT05179226Phase 3Recruiting
- Sponsor
- Pharmacosmos
- Start
- Nov 2022
- Primary completion
- Apr 2027
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ferric derisomaltose in iron deficiency anemia (IDA), sponsored by Pharmacosmos. Primary endpoint: Incidence of subjects with a Hb increase of >=1 g/dL (NDD-CKD) or 2 g/dL (intolerant or unresponsive to oral iron). Started Nov 2022; status: recruiting.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT05179226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179226.